Lipocine Inc. Income Statement
LPCN|9 years of annual SEC 10-K data (FY2013-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
Lipocine Inc. reported $11M in revenue and $8,352 in net income for FY2025. Revenue has grown at a 3.2% compound annual rate over the past 12 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.16 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.2M | -$2.9M | $500.0K | $16.1M | $16.1M | $165.0K | $428.0K | $0 | $7.7M |
| SG&A Expense | $5.0M | $4.9M | $4.1M | $5.3M | $8.2M | $5.6M | $5.3M | $10.4M | $1.6M |
| R&D Expense | $7.4M | $10.2M | $8.6M | $7.7M | $9.7M | $7.5M | $6.5M | $8.1M | $2.3M |
| Operating Income | -$1.2M | -$17.9M | -$12.1M | $3.1M | -$18.0M | -$12.9M | -$11.3M | -$19.2M | $3.9M |
| Interest Expense | - | - | $27.1K | $203.3K | $386.6K | $766.7K | - | - | - |
| Income Tax | $681 | $755 | $681 | $200 | $200 | $200 | $700 | $752 | $684 |
| Net Income | $8.4K | -$16.4M | -$10.8M | -$634.4K | -$21.0M | -$13.0M | -$11.7M | -$19.0M | $3.9M |
| EPS (Basic) | -$1.77 | -$3.10 | -$2.06 | -$0.01 | -$0.38 | -$0.50 | -$0.55 | -$1.04 | $0.85 |
| EPS (Diluted) | -$1.69 | -$3.14 | -$2.15 | -$0.01 | -$0.38 | -$0.50 | -$0.55 | -$1.04 | $0.85 |
| Shares Outstanding | 5.3M | 5.3M | 5.2M | 88.3M | 70.0M | 37.6M | 21.7M | 21.3M | 4.5M |
| Operating Margin | -10.3% | 629.0% | -2423.9% | 19.5% | -111.5% | -7818.8% | -2646.0% | - | 50.3% |
| Profit Margin | 0.1% | 573.6% | -2151.7% | -3.9% | -129.9% | -7883.7% | -2724.1% | - | 50.4% |